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Background. The concurrent use of a postprandial insulin sensitizing agent, such as bromocriptine-QR, a quick release formulation
of bromocriptine, a dopamine D2 receptor agonist, may offer a strategy to improve glycemic control and limit/reduce insulin
requirement in type 2 diabetes (T2DM) patients on high-dose insulin. This open label pilot study evaluated this potential utility
of bromocriptine-QR. Methods. Ten T2DM subjects on metformin (1-2 gm/day) and high-dose (TDID ≥ 65U/day) basal-bolus
insulin were enrolled to receive once daily (morning) bromocriptine-QR (1.6–4.8mg/day) for 24 weeks. Subjects with at least one
postbaseline HbA1c measurement (𝑁 = 8) were analyzed for change from baseline HbA1c, TDID, and postprandial glucose area
under the curve of a four-hour mixed meal tolerance test (MMTT). Results. Compared to the baseline, average HbA1c decreased
1.76% (9.74 ± 0.56 to 7.98 ± 0.36, 𝑃 = 0.01), average TDID decreased 27% (199 ± 33 to 147 ± 31, 𝑃 = 0.009), and MMTT AUC
60–240
decreased 32% (𝑃 = 0.04) over the treatment period. The decline in HbA1c and TDID was observed at 8 weeks and sustained over
the remaining 16-week study duration. Conclusion. In this study, bromocriptine-QR therapy improved glycemic control and meal
tolerance while reducing insulin requirement in T2DM subjects poorly controlled on high-dose insulin therapy.
1. Introduction
Maintenance of good glycemic control in type 2 diabetes
mellitus (T2DM) patients typically becomes progressively
more difficult as the duration of disease lengthens as a result
of continuing decline in the capacity of the pancreatic beta
cells for appropriate glucose stimulated insulin release, in the
presence of insulin resistance [1, 2]. While hyperglycemia
in patients with T2DM may be initially managed with oral
antidiabetes medications alone, added insulin therapy often
becomes necessary with longer duration of disease. This
progressive decline in beta cell function amidst a back-
ground of insulin resistance, which can be severe in many
T2DM patients, particularly with the common concomitant
presence of obesity, ultimately results in the need for high
doses of insulin in many such patients. While insulin is an
effective treatment for hyperglycemia, it carries the potential
for undesirable side effects such as hypoglycemia and weight
gain, which in turn can lead to a worsening ability to manage
diabetes [3–8]. Moreover, chronic high-dose insulin therapy
can be difficult to manage from a practical perspective, with
inherent challenges related to administration of large doses
of insulin, multiple injections, and large volume injections
(which could interfere with absorption of the insulin, thus
leading to submaximal effect of the administered insulin
dose and also adversely impacting patient comfort and
compliance) [8–11]. A plausible approach to treating such
patients with poor beta cell function and on high-dose daily
insulin may be the use of an agent with unique insulin
sensitizing properties to improve glycemic control and con-
currently reduce the daily insulin requirement. However, the
available options for such insulin sensitizing agents that are
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safe and effective are very limited. The insulin sensitizer,
pioglitazone, has been demonstrated to improve glycemia in
insulin-requiring T2DM patients [12–15]; however use of this
agent in this setting is associated with significant increased
risk for congestive heart failure in addition to weight gain
and edema [15–20]. Alternatively, circadian-timed, morning
administration of bromocriptine-QR, a quick-release, high
absorbing formulation of a potent dopamine D2 receptor
agonist, that is approved in the US for the treatment of
T2DM appears to be a unique insulin sensitizing therapy
with a good safety profile, without risk of weight gain
or hypoglycemia and with a potential to reduce adverse
cardiovascular risk [21–23]. Available evidence suggests that
bromocriptine-QR is a postprandial-weighted insulin sen-
sitizer, promoting glucose disposal following a meal, oral
glucose tolerance test, or hyperglycemic-euglycemic clamp
[24–27]. Several neurophysiological studies have implicated a
role for a diminished circadian peak of dopaminergic activity
at the biological clock (suprachiasmatic nucleus [SCN] of the
hypothalamus) in the development of insulin resistance [28–
34]. Timed bromocriptine-QR administration to restore this
diminished circadian peak of dopaminergic activity improves
insulin sensitivity [24–27]. Preclinical studies suggest that
such effects are mediated via a circadian-time-dependent
effect to ameliorate aberrations in hypothalamic activities
that potentiate insulin resistance and loss of appropriate fuel
sensing mechanisms [28–34]. In humans, this daily peak
central dopaminergic activity is believed to occur in the
morning circa awakening and to be diminished in T2DM [24,
35]. Consequently, we hypothesized that an additive or supra-
additive interaction may exist between bromocriptine-QR
and basal plus prandial insulin therapy, with bromocriptine-
QR providing the enhanced responsiveness to the exogenous
prandial insulin therapy to produce greater postprandial
blood glucose lowering with lower insulin requirement. We
therefore explored in a small open label pilot study the poten-
tial utility of morning bromocriptine-QR therapy to improve
glycemic control and reduce daily insulin requirement in
T2DM subjects on high-dose (≥65U/day) insulin therapy
that incorporates a prandial insulin administration.
2. Methods
2.1. Subjects and Study Design. Ten subjects with T2DM
treated with high-dose insulin [total daily insulin dose
(TDID) ≥ 65 units/day] and metformin (1-2 g in divided
doses) were recruited from the outpatient primary care and
diabetes clinics at Parkland Memorial Hospital or through
self-referral at the Clinical Diabetes Office at the University
of Texas Southwestern Medical Center in Dallas, TX, and
assigned to bromocriptine-QR therapy (see below for dosing
regimen). Patients between ages 30 and 65 years with the
clinical diagnosis of T2DM on multiple daily injections of
insulin (MDI insulin) plus metformin and HbA
1c between
7.5 and 12.0% were eligible. Major exclusion criteria for study
participation were pregnancy, lactation, type 1 diabetes, ele-
vated serum creatinine over 1.5mg/dL, elevated liver function
tests above 3-fold the upper limit reference range, and a
recent history of substance abuse. In addition, patients with
a risk of hypotension, recent blood donation in the past
30 days, syncopal migraines, gastroparesis, autonomic neu-
ropathy, hypoglycemia unawareness, uncontrolled mental
illness and/or psychosis, and variable sleep patterns (e.g., shift
workers) were excluded. Five additional patients with similar
demographics as the bromocriptine-QR treated group were
recruited under the same study protocol only as a reference
for glycemic control achievable only by increasing insulin
dose (i.e., absent bromocriptine-QR therapy). In this pilot
study design, this reference group was not randomized nor
placebo-treated nor able to serve as an active comparator
for efficacy due to allowance of insulin dose change during
the study and of too small N to serve as a control group for
noninferiority testing. The study protocol was approved by
the institutional review board (IRB) of theUniversity of Texas
SouthwesternMedical Center,Dallas, TX, and all participants
provided written informed consent prior to enrollment.
The study protocol was registered with ClinicalTrials.gov
(Identifier: NCT01474018).
2.2. Treatment Paradigm. Patients continued baseline treat-
ment with metformin (1-2 gm in divided doses) and MDI
insulin (either premixed human 70/30 insulin twice daily or
basal-bolus regimen with basal insulin glargine [rDNA ori-
gin; Lantus, Sanofi, Paris, France] and insulin aspart [rDNA
origin; Novolog,NovoNordisk, Bagsvaerd,Denmark] at each
meal). Bromocriptine-QR was titrated weekly according to a
schedule used in previous studies and detailed on the FDA-
approved package insert; 1 tablet (0.8mg) is taken within 2
hours of waking for the first week and each week thereafter;
an additional tablet is added until a maximum tolerated dose
of two to six tablets (1.6 to 4.8mg, resp.) during week six
was achieved. Patients were contacted by phone each week
during the titration period to inquire about hypoglycemia
and potential side effects, primarily nausea, headache, and
dizziness. If intolerable side effects were encountered, the
patient was instructed to reduce the dose to the highest
previously tolerated dose and continue taking this dose
through the remainder of the 24-week trial. Metformin dose
was held constant. Insulin was titrated according to good
clinical practice to target an HbA
1c ≤ 7.0%, while minimizing
hypoglycemia.
2.3. Measurements. HbA
1c levels and total daily insulin dose
requirements were assessed at enrollment and weeks 8, 16,
and 24. HbA
1c was measured using high performance liquid
chromatography in the UTSW Clinical Diabetes Labora-
tory. At baseline and week 24, a four-hour mixed meal
tolerance test (MMTT) was performed in the fasting state
with antidiabetic treatments withheld prior to and during
the MMTT to evaluate the impact of bromocriptine-QR
therapy upon fasting and postprandial blood glucose levels.
Antidiabetes medications were withheld prior to and during
the MMTT to assess the impact of bromocriptine-QR on
endogenous insulin-mediated glucose disposal without inter-
ference/confounding of results from a potentially changed
exogenous insulin dose requirement during the study period.
A four-hour challenge was selected to better quantify
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the glucose profile which does not normalize within 3 hours
in patients with T2DM. A mixed carbohydrate/fat meal
was simulated with Boost concentrate 1 gm/kg carbohydrate
equivalent ingested over 5 minutes. Glucose levels were
measured at 0, 15, 30, 60, 90, 120, 150, 180, and 240 minutes
following ingestion. The area under the curve (AUC) for
postprandial glucose response [total (0–240 minutes) and
postabsorptive (60–240 minutes)] was calculated.
2.4. Statistics. Statistical analyses were performed to assess
within group pre- versus posttreatment differences. Analyses
of the study endpoints used the modified intention-to-treat
population of subjects defined as those having at least one
postinitiation HbA
1c data point utilizing the last observation
carry forward method for missing data. Statistical analyses
were performed using SPSS Version 19.0 (Armonk, NY: IBM
Corp.). The change over time in the HbA
1c level and the total
daily insulin dose requirement were analyzed by repeated
measures analysis of variance (ANOVA). Paired, two-tailed
t-tests were performed for pre- versus post-8- and 24-week
comparisons of HbA
1c, total daily insulin dose requirement,
and the 24-week AUC of postprandial (0–240 and 60–
240 minutes) blood glucose during the MMTT. Statistical
significance was accepted at the 𝑃 < 0.05 level. Data are
presented as mean and standard error of the mean (SEM).
3. Results
Of the 10 subjects recruited, two withdrew consent prior to
the first HbA
1c data point assessment and a third patient was
lost to follow-up after the week 8 visit assessment, while on
1.6mg/day of bromocriptine-QR. Seven subjects completed
the study. Of the seven subjects that completed the study, five
achieved the maximum bromocriptine-QR dose of 4.8mg
daily and 2 subjects stopped dose titration at 1.6mg daily
due to nausea and headaches and continued this dose for
the duration of the study. Statistical analyses were performed
on the 8 subjects with a postinitiation HbA
1c value. All 5
patients in the reference group completed the study.The study
subjects were predominantly black and Hispanic and obese.
The baseline demographics of the study subjects are displayed
in Table 1.
There was an overall significant decrease in HbA
1c (𝑃 =
0.004, ANOVA) (Figure 1(a)) and total daily insulin dose
(𝑃 = 0.001, ANOVA) (Figure 1(b)) over the 24-week
bromocriptine-QR treatment period. Following 24 weeks of
bromocriptine-QR therapy, the average HbA
1c decreased by
1.76% compared to the baseline (from 9.74±0.56 to 7.98±0.36,
𝑃 = 0.01) (Figure 1(a)). Two of the 8 patients achieved
an HbA
1c less than 7.0% (from 8.3% to 6.9% and 11.3 to
6.7%, resp.). Furthermore, this improvement in HbA
1c was
accompanied by a concurrent reduction in the average daily
insulin requirement by 27% (TDID from 199±33 to 147±31,
𝑃 = 0.009) (Figure 1(b)). The decline in HbA
1c and in the
TDIDwere observed at 8weeks of treatment with averageA1c
decreasing by 1.86% (from 9.74±0.56 to 7.88±0.29,𝑃 = 0.01)
with a concurrent 28.6% reduction in average daily insulin
requirement (TDID from 199 ± 33 to 142 ± 27, 𝑃 = 0.01)
Table 1: Baseline demographics of the study subjects.
Bromocriptine-QR
treatment group
(𝑁 = 8)
Reference group
(𝑁 = 5)
Age (years) 46 ± 3 54 ± 3
Gender (% female) 88 40
Race 63% B; 25% H;12%W
60% B; 40% H;
0%W
Weight (lbs) 252.3 ± 20 227.2 ± 17.4
BMI 46.2 ± 5.9 37.1 ± 5.3*
Duration of diabetes
(years) 13.7 ± 2.2 12.6 ± 3.5
HbA1c 9.74 ± 0.56 9.68 ± 0.74
Total daily dose of
insulin (units) 199 ± 33 105 ± 41
*Mean does not include one double amputee subject.
B: black; H: Hispanic; W: white; BMI: body mass index.
and were sustained over the remaining 16-week study dura-
tion (Figures 1(a) and 1(b)). The bromocriptine-QR induced
improvement in HbA
1c was associated with a significant
reduction in mixed meal tolerance test postprandial glucose
AUC tested during the postabsorptive phase (AUC
60–240, 32%
reduction, 𝑃 = 0.04) (Figure 2). The MMTT AUC
0–240 also
showed a trend of reduction in glucose levels that approached
but did not achieve statistical significance (29% reduction,
𝑃 = 0.057). There was no significant difference from baseline
in the fasting glucose checked at initiation of the MMTT
(conducted in the absence of any antidiabetesmedications on
the day of testing) (fasting glucose 243±31mg/dL at baseline
versus 229 ± 16mg/dL at 24 weeks).
In contrast, in the reference group, where the treat-to-
target goal could be achieved only by raising the insulin dose,
a nonstatistically significant 1.08% A1c drop from baseline
(from 9.68 ± 0.74 to 8.6 ± 0.62; 𝑃 = 0.19) with no change
in fasting or postprandial glucose response during the mixed
meal tolerance test was observed over the 24-week study
period, while subjects increased the average total daily insulin
dose by 26% from 105 ± 41 to 135 ± 49 units.
4. Discussion
This pilot study is the first demonstration of an effect of
morning bromocriptine-QR therapy to improve glycemic
control while enabling a reduction in total daily insulin
dose requirement in T2DM subjects whose glycemia was
inadequately controlled (HbA
1c > 7.5%) on metformin
plus high-dose (TDID insulin ≥ 65 units/day) MDI insulin
therapy. Addition of bromocriptine-QR therapy to high-
dose basal plus prandial insulin regimens resulted in a
significant 1.76% HbA
1c reduction with a concurrent 27%
reduction in daily insulin dose requirement. Such a response
to bromocriptine-QRwas also coupled to a 32% improvement
in the MMTT glucose levels conducted in the absence of
any insulin dosing. Contrariwise, increasing the daily insulin
dose by 26% from 105 to 132U/day was without significant
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Figure 1: Effect of bromocriptine-QR therapy on HbA
1c (Panel (a)) and total daily insulin dose (TDID) (Panel (b)) over 24 weeks in subjects
on metformin plus high-dose basal-bolus insulin therapy at baseline.
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Figure 2: Effect of bromocriptine-QR therapy onmixed meal toler-
ance test postprandial glucose area under the curve (AUC) over 24
weeks in subjects on metformin plus high-dose basal-bolus insulin
therapy at baseline.
improvement in glycemic control in the reference group.
Although not specifically tested, these findings support a
potential insulin sensitizing effect of bromocriptine-QR in
this subject population, which is in agreement with previous
preclinical and clinical studies suggesting a postprandial-
weighted insulin sensitizing effect of this therapy [24–27, 36,
37]. It should be noted that, in the present study, the MMTT
was conducted in the absence of any antidiabetes agent
including insulin on the day of the test. Given previous study
results demonstrating bromocriptine-QR’s effect to improve
postprandial insulin sensitivity, its effect on the MMTT
would be expected to have been even greater if conducted
in the presence of exogenously administered prandial insulin
even at its reduced dose after 24 weeks of bromocriptine-
QR therapy. In agreement with the present findings and this
tenet are the observations that timed bromocriptine therapy
improvedmaximally insulin stimulated glucose disposal dur-
ing a euglycemic-hyperinsulinemic clamp in severely insulin
resistant T2DM subjects on oral antidiabetes agents [25].
Moreover, in insulin resistant animals, the effect of exogenous
insulin administration on glucose disposal and glucose toler-
ance AUC glucose and insulin were each markedly enhanced
in animals pretreated with timed daily bromocriptine admin-
istration for a two-week period. Such bromocriptine-QR
treatment in animals also improves glucose disposal during
a hyperglycemic-hyperinsulinemic clamp [26, 27, 36, 37]. By
extension, combination of bromocriptine-QR therapy with
prandial insulin secretagogues, such as the incretin-mimet-
ics, may also produce similar additive or supra-additive
effects as indicated in preclinical studies [38].
Available evidence suggests that timed bromocriptine
therapy improves insulin sensitivity and dysglycemia by
correcting hypothalamic activity aberrations that potentiate
insulin resistance ([30], reviewed in [31]). In normal insulin
sensitive states, hypothalamic fuel sensing neurons detect the
meal-associated rise in plasma and brain levels of glucose
and free fatty acids and, via the neuroendocrine axis, send
signals to the peripheral tissues to improve insulin-stimulated
glucose disposal, reduce hepatic glucose output, and reduce
adipose tissue lipolysis [39–43]. However, in insulin resistant
states, such hypothalamic fuel sensing is diminished and
consequently these hypothalamic directed responses to pro-
duce the above effects in the periphery are also diminished.
Resultantly, such hypothalamic aberrations are causative in
the insulin resistance and contribute to postprandial hyper-
glycemic dysglycemia. Importantly, recent studies indicate
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a role for diminished hypothalamic dopaminergic activity in
such aberrant hypothalamic fuel sensing [28, 30, 31, 34, 36,
37, 44–46].
Neurophysiological studies of hypothalamic regulation
of fuel metabolism in normal and insulin resistant states
indicate that central dopaminergic activitiesmodulate insulin
sensitivity as follows. In insulin resistant states, the nor-
mal daily peak in dopaminergic activity at the biological
clock (hypothalamic SCN) is diminished and reinstating this
peak with systemic, central, or direct (to the SCN itself)
dopaminergic agonist reverses the insulin resistance ([28,
36, 37, 44, 45], Cincotta and Luo unpublished data). It
has been observed that such reductions in hypothalamic
dopaminergic activity in insulin resistant states are coupled
to elevations of noradrenergic and serotonergic activities
at the ventromedial hypothalamus (VMH) and elevated
Neuropeptide Y and corticotropin releasing hormone levels
at the hypothalamic paraventricular nucleus (PVN), in which
neurophysiological alterations have been shown to markedly
potentiate insulin resistance in part via a concurrent loss of
appropriate hypothalamic fuel sensing (as discussed above)
and an elevation of sympathetic tone in the periphery [30–
34, 46]. Timed daily administration of bromocriptine to
reestablish the daily peak in SCN dopaminergic activity also
reverses the VMH and PVN abnormalities described above
[30, 37, 46] and improves postprandial insulin resistance
(even via its intracerebroventricular administration) [26, 30,
45]. Additionally, a large and growing body of evidence impli-
cates functional roles for decreased mesolimbic dopamine
activity in the onset of insulin resistance [47–52] and this
neural center is also under the influence of the SCN (reviewed
in [53]). Restoration of the circadian peak in central nervous
system (hypothalamic) dopaminergic neuronal activity may
represent a potential therapeutic target to improve glycemic
control in T2DM patients requiring high-dose basal-bolus
insulin therapy.
Limitations of this study include the small sample size
and no direct measure of insulin sensitivity or beta cell
function.However, the significant findings noted in this small
pilot study indicate that a trial with a larger sample size
and assessing beta cell function and insulin sensitivity is
warranted.
In conclusion, bromocriptine therapy in T2DM patients
on high-dose insulin and with poor glycemic control
improved glycemic control and meal tolerance while simul-
taneously allowing for a reduction in the daily insulin dose
requirement.
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